THERMO FISHER SCIENTIFIC INC
2,744 institutions still hold THERMO FISHER SCIENTIFIC INC as of Q1 2026. Tracked across SEC 13F-HR filings, with insider and 13D/G activity surfaced alongside.
TMO Q1 2026 institutional ownership is a $156.5B book across 2,520 holders. BlackRock is the largest holder at $14.9B (30.5M shares, -15.8%, -$2.8B) -- the largest seller. Vanguard Capital Management is second at $11.9B (24.3M shares, NEW after three-way split); State Street is third at $8.2B (16.7M shares, slight value decline); Morgan Stanley is fourth at $5.3B (10.9M shares, -22.4%, -$1.6B); FMR/Fidelity is fifth at $5.3B (10.8M shares, +5.6%, +$423M). Capital International Investors NEW large position at $1.9B (3.9M shares) -- from effectively zero in Q4. Capital Research Global Investors increased +$481M (+22.2%) from $1.7B to $2.2B. MassFinancial $2.3B (slight value decline). Geode Capital $4.1B (slight increase). Franklin Resources $3.3B (+6.7%). JPMorgan $3.3B (+6.2%, +$552M). Vanguard Portfolio Management $3.0B (NEW after split); Vanguard Fiduciary Trust $1.0B (NEW after split) -- total Vanguard passive exposure $15.3B. Bank of America $2.7B (-6.4%, -$725M). Northern Trust $1.7B (-2.8%, -$320M). Goldman Sachs $1.6B (slight increase). Charles Schwab $1.4B (slight increase). DZ Bank $1.4B (-8.3%, -$614M). RBC $1.9B (-3.5%, -$416M). BNY Mellon $1.9B (+1.0%, -$307M mark-to-market). Pictet Asset Management $1.0B (-6.2%, -$414M). New positions: Capital International NEW; Vanguard three entities NEW. The 75.50 whaleScore reflects AUM. Smart-money-signal read: TMO Q1 2026 holder flows are net-bearish, dominated by three Capital Research vehicles rotating out: Capital World -$3.1B (-33.1%), BlackRock -$2.8B (-15.8%), Morgan Stanley -$1.6B (-22.4%). State Street also reduced. The buyers (Fidelity +$423M, JPMorgan +$552M, Capital Research Global +$481M, Capital International NEW $1.9B) are smaller than the sellers in absolute terms. The Capital Research bifurcation (World selling, Global buying, International entering) suggests internal reallocation across strategies rather than a unified directional view. The net read is cautious: mega-holders trimming life-sciences exposure may reflect sector rotation or valuation concerns after a strong 2024-2025 run.
Top holders
Sorted by position value. Source: SEC EDGAR 13F-HR filings.